ACET: Adicet Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
Stocks in this Quantisnow insightHealth Care
Historical context for ACET
Across the 15 sessions after earlier ACET headlines, the stock closed higher 9 times and lower 6 times, with a median move of 5.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ACET | SPY |
|---|---|---|---|
| Sep 1, 2026 | Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Updateand 1 other headline that session | +6.4% | -0.7% |
| Aug 28, 2026 | Adicet Bio Announces FDA Clearance of IND Application for ADI-212 | +0.6% | -0.2% |
| Aug 6, 2026 | Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates | -13.4% | -0.2% |
| Jul 22, 2026 | Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference | +5.5% | -0.1% |
| May 15, 2026 | Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference | -8.7% | -1.2% |
| May 14, 2026 | Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates | +4.2% | +0.8% |
Quantisnow market dataNASDAQ
ACET
Adicet Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for ACET
Full ACET profile on Quantisnow Follow ACET and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time